Relapse-onset MS patients have a substantially reduced risk of contrast-enhancing lesions or new T2 lesions after they reach age 50 years, according to a longitudinal analysis of the Amsterdam MS cohort study (Coerver et al. Eur J Neurol 2023;30:2385-2392). Read More
Latest News
EAN HIGHLIGHTS 2023 – WEDNESDAY, JULY 5 EDITION
July 5, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Ofatumumab – 5-year efficacy data
MS influenced by prior pregnancies
NfL not useful to predict cognitive impairment
Improved outcome with autoimmune comorbidity in MS
Clinical tip of the day Read More
EAN HIGHLIGHTS 2023 – TUESDAY, JULY 4 EDITION
July 4, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Update on BTK inhibitors
Adding OCT to the McDonald criteria
How does cognitive impairment progress?
Clinical tip of the day Read More
EAN HIGHLIGHTS 2023 – MONDAY, JULY 3 EDITION
July 3, 2023Selected highlights from the European Academy of Neurology annual meeting, Budapest, Hungary, July 1-4, 2023.
Few patients achieve an optimal response with platform therapies
Fluid biomarkers predict early disease activity
When does PIRA start?
MOG antibodies uncommon
Clinical tip of the day Read More